For frail patients with multiple myeloma, receiving more intensive therapy, triplet bortezomib-lenalidomide-dexamethasone (VRd) rather than doublet lenalidomide-dexamethasone (Rd), is a more-effective treatment, according to a recent study of patients treated in VA facilities.
Targeted Therapies for CLL Widely Used at VA; Prolonged Survival
U.S. military veterans with chronic lymphocytic leukemia (CLL) routinely received therapies in line with current evidence-based treatment practices over the past two decades, and those who were treated with targeted therapies had longer overall survival, according to a national VA study with more than 20 years of clinical data.
Bladder, Kidney Cancer Rates Lower in Younger Servicemembers vs. Civilians
Younger military servicemembers have lower rates of bladder and kidney cancer than a similar civilian cohort, but that appears to change with age.
Guideline Discordant Care Leads to Lower NSCLC Survival in AI/AN
American Indian/Alaska Native (AI/AN) patients have lower overall survival rates from non-small cell lung cancer (NSCLC), and at least part of the reason is that they are less likely to receive guideline-concordant care, according to a new study.
Lung Cancer Survival Rates Continue Improvement Within VHA
VA’s increasing usage of cutting-edge diagnostic and therapeutic treatments for lung cancer, as well as its equal access model to address healthcare disparities, could be a model for other medical systems, according to a new study.
Veterans Study Found Positive Sotorasib Results Similar to CodeBreak Trials
Three years ago, based on the CodeBreak100 trial, the Food and Drug Administration granted accelerated approval to the KRAS G12C inhibitor sotorasib for treating advanced non-small cell lung cancer in the second line or later.
Immune Checkpoint Inhibitors Improve Overall Survival for VA NSCLC Patients
DURHAM, NC -- Non-small-cell lung cancer (NSCLC) patients showed significant benefit from the use of immune checkpoint inhibitors (ICIs) in a study looking at use of the therapy for five major cancer types in the VA healthcare system. The study from the VA’s National...
High Intensity of End-of-Life Care for Minority Patients With Lung Cancer
While disparities in lung cancer mortality among racial and ethnic minorities are well documented, not as much is understood about how racial and ethnic minority patients with lung cancer are treated at the end of life.
Risk Model Helps Predict Second Lung Cancer in Survivors of Initial Malignancy
Lung cancer survivors have a high risk of developing second primary lung cancer (SPLC); the risk is three to four times higher than the risk of someone in the general population developing initial primary lung cancer (IPLC).
Shields Helped Implement Program to Bring Infusion Closer to VHA Patients
The idea for VA’s Close To Me Infusion Service has its roots in many places, One of them a veteran that Jenna Shields, PharmD, BCOP, saw weekly at the Pittsburgh VAMC.
Military Healthcare Beneficiaries Have Better NSCLS Survival.
Does the universal healthcare provided by the U.S. military health system (MHS) mean better lung cancer survival for patients? A new study suggested that is the case.
Real-World Pneumonitis Rates After Chemotherapy Plus Durvalumab
ANN ARBOR, MI – While adjuvant durvalumab after definitive chemoradiotherapy (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) is well-tolerated in clinical trials, that is not always the case in the real-world, according to a new VA study....
NSCLC Survival Rates Higher with Distant Recurrence vs. De Novo Metastasis
PALO ALTO, CA – Even with new and improved therapies, clinicians remain challenged by how to deal with advanced lung cancer. “The survival profile of patients with metastatic lung cancer remains poorly understood by metastatic disease type (i.e., de novo stage IV vs....
Biomarkers Predict Survival, Risk of Adverse Effects in Metastatic NSCLC
ANN ARBOR, MI – Lung cancer outcomes have been significantly improved with the use of immune checkpoint inhibitors (ICI), although some patients derive only limited benefit from the therapy and others experience potentially serious toxicities. That’s why a new study...
No Racial Differences in DLBCL Treatment Within VA Healthcare System
No statistically significant racial differences in diffuse large B-cell lymphoma (DLBCL) outcomes were found for patients treated within the VHA, according to recent research.
Very Elderly Patients Fare Much Worse When Treated for DLBCL
Diffuse large B-cell lymphoma (DLBCL) becomes much more difficult to treat in older patients, according to a new study suggesting that more adults of advanced age be included in clinical trials for new agents.
Despite Disparities, Making a Difference for Veterans With Relapsed DLBCL
DURHAM, NC—Recent Food and Drug Administration approvals of chimeric antigen receptor (CAR) T cell therapies and novel immunotherapies have helped to significantly improve outcomes for patients with relapsed and refractory diffuse large B cell lymphoma (R/R DLBCL)....
More Diverse Dataset Raises Questions about MGUS Risk Models
Patients with monoclonal gammopathy of undetermined significance (MGUS) have been thought to have a less than 1% chance of progressing to multiple myeloma as long as their M-protein levels are below 1.5 g/dL.
Lower Relapse Rates Suggest Limited Value for Prophylaxis in DLBCL
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or progress following first-line chemoimmunotherapy.
For CLL, BTK Inhibitors Appear to Extend Time to Next Line Most
JACKSONVILLE, FL—As treatment options for chronic lymphocytic leukemia (CLL) multiply, physicians face an increasing array of sequencing options but have little guidance from clinical trials of the most effective order given each patient’s specific disease...
MGUS Higher in Servicemembers, No Association Seen With Burn Pit Exposure
Individuals who have served in the U.S. military have about three times the risk of monoclonal gammopathy of undetermined significance (MGUS) as a similarly aged cohort in the Icelandic iStopMM study.
Mental Health Issues Increase Mortality in Some Veterans With AML
Venetoclax combinations are common treatments for individuals with acute myeloid leukemia (AML) who are unable to withstand the rigors of intensive induction chemotherapy.
BTK Inhibitors Provide Option for CLL Patients With Severe Renal Dysfunction
BTK inhibitors have proven to be a powerful tool in CLL treatment and have replaced chemoimmunotherapy as the preferred first-line treatment.
Evaluate Veterans With MGUS for Cardiovascular Disease
Monoclonal gammopathy of undetermined significance (MGUS) is not considered a hematological condition of concern, yet it is associated with lower overall survival. VA researchers led by Lawrence Liu, MD, of the St. Louis VAMC, explored whether the reduced life expectancy arose from an increased risk of cardiovascular events.
Deployment Linked to Longer Survival in Servicemembers, Veterans With NHL
A study presented at the 2023 ASH Conference, provided additional evidence for the healthy deployer effect, this time in individuals with non-Hodkin lymphoma.
Which Veterans Should Undergo SPEP Testing for Plasma Cell Dyscrasia?
Plasma cell dyscrasia affects up to 5% of adults. While often asymptomatic, its characteristic clonal expansion of bone marrow plasma cells can also indicate the presence of several hematological malignancies including multiple myeloma.
GLP-1 Use Reduces Risk of MGUS Progression in Some Veterans
Glucagon-like peptide 1 (GLP-1) receptor agonists have gained huge popularity as they have demonstrated the ability to substantially reduce both blood-glucose levels and weight. In addition, recent research suggests cardiovascular and renal benefits to their use in certain populations.
Agent Orange Increases CVD Risk in Veterans With Myeloproliferative Neoplasms
As Vietnam-era veterans move into the age range in which most myeloproliferative neoplasms (MPNs) develop, the VA has a keen interest in fully understanding the full impact of exposure to Agent Orange in veterans with these malignancies.
Thrombosis Risk With Cancer Treatment Varies With VA Patient Characteristics
Has cancer-directed therapy changed patterns of the incidence and risk of cancer-associated thrombosis (CAT) at the VA?
High Serum TARC Levels Predict Hodgkin Lymphoma Years Before Diagnosis
Could high levels of the chemokine TARC produced in tumor cells in classic Hodgkin lymphoma help predict the malignancy?